Clinical evaluation of matrix metalloproteinases as early diagnostic markers of peritoneal deterioration and encapsulating peritoneal sclerosis.

Clinical evaluation of matrix metalloproteinases as early diagnostic markers of peritoneal deterioration and encapsulating peritoneal sclerosis. - Multicenter analysis in Japan: original indicator of peritoneal deterioration (MAJOR-PD)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010572

Enrollment

400

Registered

2013-04-30

Start date

2004-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

encapsulating peritoneal sclerosis (EPS)/ sclerosing encapsulating peritonitis(SEP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients treated with peritoneal dialysis.

Exclusion criteria

Exclusion criteria: patients infected with pathogenic organism or virus.

Design outcomes

Primary

Measure	Time frame
Clinical evaluation of matrix metalloproteinase level in drained dialysate, mesothelial cell area or others in encapsulating peritoneal sclerosis patients.	—

Secondary

Measure	Time frame
Clinical evaluation of correlation between peritoneal function and matrix metalloproteinase level in drained dialysate, mesothelial cell area or others in PD patients.	—

Countries

Japan

Outcome results